Currently, over 80 studies registered in clinicaltrials.gov are studying both the safety and potential efficacy of complementing traditional anti-cancer approaches with small molecules or survivin-targeting vaccines, thus increasing the overall sensitivity of cancer cells to anti-cancer treatments [52]. This evidence concerns the gene BIRC5 and cancer.